Russell Investments Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $942M | Sell |
781,929
-7,815
| -1% | -$7.98M | 0.83% | 13 |
|
|
2026
Q1 | $720M | Buy |
789,744
+123,276
| +18% | +$125M | 0.77% | 12 |
|
|
2025
Q4 | $717M | Buy |
666,468
+79,570
| +14% | +$76.1M | 0.78% | 12 |
|
|
2025
Q3 | $445M | Buy |
586,898
+29,188
| +5% | +$21.7M | 0.5% | 19 |
|
|
2025
Q2 | $434M | Sell |
557,710
-97,917
| -15% | -$76.1M | 0.55% | 17 |
|
|
2025
Q1 | $541M | Sell |
655,627
-68,889
| -10% | -$57.3M | 0.74% | 13 |
|
|
2024
Q4 | $559M | Buy |
724,516
+61,998
| +9% | +$51.3M | 0.77% | 13 |
|
|
2024
Q3 | $586M | Buy |
662,518
+84,310
| +15% | +$75.8M | 0.85% | 11 |
|
|
2024
Q2 | $524M | Buy |
578,208
+7,802
| +1% | +$6.24M | 0.84% | 10 |
|
|
2024
Q1 | $444M | Buy |
570,406
+53,602
| +10% | +$38.1M | 0.7% | 12 |
|
|
2023
Q4 | $301M | Buy |
516,804
+8,309
| +2% | +$4.85M | 0.54% | 19 |
|
|
2023
Q3 | $274M | Buy |
508,495
+33,377
| +7% | +$17.2M | 0.54% | 20 |
|
|
2023
Q2 | $222M | Sell |
475,118
-38,910
| -8% | -$16.3M | 0.43% | 30 |
|
|
2023
Q1 | $176M | Buy |
514,028
+52,836
| +11% | +$17.8M | 0.35% | 45 |
|
|
2022
Q4 | $169M | Buy |
461,192
+18,214
| +4% | +$6.46M | 0.35% | 44 |
|
|
2022
Q3 | $144M | Sell |
442,978
-2,469
| -0.6% | -$782K | 0.32% | 49 |
|
|
2022
Q2 | $144M | Buy |
445,447
+20,790
| +5% | +$6.24M | 0.29% | 55 |
|
|
2022
Q1 | $122M | Sell |
424,657
-30,380
| -7% | -$7.82M | 0.21% | 93 |
|
|
2021
Q4 | $126M | Buy |
455,037
+51,730
| +13% | +$13.1M | 0.2% | 99 |
|
|
2021
Q3 | $93.1M | Buy |
403,307
+11,226
| +3% | +$2.77M | 0.16% | 144 |
|
|
2021
Q2 | $90M | Buy |
392,081
+16,627
| +4% | +$3.34M | 0.15% | 147 |
|
|
2021
Q1 | $70.1M | Sell |
375,454
-327,401
| -47% | -$64M | 0.12% | 180 |
|
|
2020
Q4 | $118M | Sell |
702,855
-846
| -0.1% | -$126K | 0.23% | 76 |
|
|
2020
Q3 | $104M | Buy |
703,701
+145,227
| +26% | +$22.5M | 0.22% | 81 |
|
|
2020
Q2 | $91.5M | Buy |
558,474
+55,992
| +11% | +$8.59M | 0.2% | 99 |
|
|
2020
Q1 | $69.7M | Buy |
502,482
+169,278
| +51% | +$23.3M | 0.18% | 118 |
|
|
2019
Q4 | $43.8M | Buy |
333,204
+10,264
| +3% | +$1.19M | 0.08% | 288 |
|
|
2019
Q3 | $36.1M | Sell |
322,940
-88,106
| -21% | -$9.81M | 0.07% | 333 |
|
|
2019
Q2 | $45.6M | Sell |
411,046
-48,814
| -11% | -$5.75M | 0.09% | 285 |
|
|
2019
Q1 | $59.6M | Sell |
459,860
-240,341
| -34% | -$29.2M | 0.11% | 204 |
|
|
2018
Q4 | $80.8M | Sell |
700,201
-206,639
| -23% | -$23.1M | 0.18% | 112 |
|
|
2018
Q3 | $97.2M | Buy |
906,840
+188,150
| +26% | +$18.8M | 0.18% | 105 |
|
|
2018
Q2 | $61.4M | Buy |
718,690
+17,955
| +3% | +$1.47M | 0.13% | 161 |
|
|
2018
Q1 | $54.1M | Buy |
700,735
+100,928
| +17% | +$8.13M | 0.09% | 259 |
|
|
2017
Q4 | $51M | Sell |
599,807
-277,911
| -32% | -$23.6M | 0.09% | 275 |
|
|
2017
Q3 | $75.1M | Buy |
877,718
+206,391
| +31% | +$16.9M | 0.13% | 182 |
|
|
2017
Q2 | $55.3M | Buy |
671,327
+48,706
| +8% | +$3.97M | 0.1% | 244 |
|
|
2017
Q1 | $52.4M | Sell |
622,621
-94,980
| -13% | -$7.61M | 0.1% | 252 |
|
|
2016
Q4 | $52.8M | Buy |
+717,601
| New | +$53.4M | 0.1% | 222 |
|
Other funds holding LLY
Russell Investments Group's LLY Position: Q2 2026 in Review
Russell Investments Group reduced its Eli Lilly (LLY) stake by 0.99% in Q2 2026, selling an estimated $7.98M and leaving 781,929 shares worth $942M. The position accounts for 0.83% of the portfolio, ranked #13.
Russell Investments Group first reported a position in LLY in Q4 2016 and has held it in 39 quarters since. 4,630 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Russell Investments Group held 781,929 shares of Eli Lilly worth $942M as of Q2 2026.
- Russell Investments Group sold 7,815 Eli Lilly shares in Q2 2026, an estimated $7.98M.
- Eli Lilly made up 0.83% of Russell Investments Group's portfolio in Q2 2026, its #13 holding.
- Russell Investments Group first reported a position in Eli Lilly in Q4 2016 and has held it in 39 quarters since.
- 4,630 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.